Current Report Filing (8-k)
06 May 2021 - 6:02AM
Edgar (US Regulatory)
0001034842
false
0001034842
2021-05-05
2021-05-05
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 5, 2021
RIGEL PHARMACEUTICALS, INC.
(Exact name of registrant as specified in
its charter)
Delaware
(State or other jurisdiction of incorporation)
0-29889
|
|
94-3248524
|
(Commission File No.)
|
|
(IRS Employer Identification No.)
|
|
|
|
1180 Veterans Boulevard
|
|
|
South San Francisco, CA
|
|
94080
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including area code: (650) 624-1100
Not Applicable
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
Title of Each Class
|
|
Trading
Symbol(s)
|
|
Name of Each Exchange on Which
Registered
|
Common Stock, par value $0.001 per share
|
|
RIGL
|
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of
the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with
any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02.
|
Results of Operations and Financial Condition.
|
On May 5, 2021, Rigel Pharmaceuticals, Inc.
(“Rigel”) announced certain financial results for its first quarter ended March 31, 2021. A copy of Rigel’s press release,
titled “Rigel Reports First Quarter 2021 Financial Results and Provides Business Update,” is furnished pursuant to Item 2.02
as Exhibit 99.1 hereto.
The information in this report, including the
exhibit hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended,
or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information
contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange
Commission made by Rigel, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
|
Item 9.01.
|
Financial Statements and Exhibits.
|
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: May 5, 2021
|
RIGEL PHARMACEUTICALS, INC.
|
|
|
|
By:
|
/s/ Dolly A. Vance
|
|
|
Dolly A. Vance
|
|
|
Executive Vice President, General Counsel and Corporate Secretary
|
Rigel Pharmaceuticals (NASDAQ:RIGL)
Historical Stock Chart
From Apr 2024 to May 2024
Rigel Pharmaceuticals (NASDAQ:RIGL)
Historical Stock Chart
From May 2023 to May 2024